Drugs / CD70-targeting CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05947487 | Jul 2023 → Dec 2025 overdue | cancer | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05948033 | Jul 2023 → Dec 2025 overdue | lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD70-targeting CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05948033 ↗ |
| Modality | Cell therapy | “autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy” NCT05947487 ↗ |